Health🇺🇸 🇩🇰· 24 hours agoNovo defends suit over Lilly weight-loss ads as GLP-1 rivalry growsWhat's new: Novo argues Lilly's ads compare Zepbound with older Wegovy doses, not the 7.2 mg version cleared in March.#Novo Nordisk#Eli LillyCNBC, MarketWatch +1